My SciELO
Services on Demand
Journal
Article
Indicators
Cited by SciELO
Access statistics
Related links
Cited by Google
Similars in SciELO
Similars in Google
Share
Archivos Españoles de Urología (Ed. impresa)
Print version ISSN 0004-0614
Abstract
SANCHEZ-SALMON, Aida and RUIBAL, Álvaro. Current value of positron emission tomography for prostate cancer follow-up. Arch. Esp. Urol. [online]. 2006, vol.59, n.10, pp.1021-1029. ISSN 0004-0614.
Positron emission tomography (PET) is a non-invasive nuclear medicine technology which uses radiotracers and cameras slightly different from the ones used in other nuclear medicine tests. Most current indications are for oncological diseases; in nephrology-urology its use has been reduced because of the characteristics of the most commonly used radiotracer,18F-fluor deoxiglucose (18F-FDG, a glucose analogue), which is excreted by the kidney, limiting the interpretation of the study in urologic malignancies. Currently, 18F-choline is a promising radiotracer for both staging and restaging, especially if hybrid PET/CT scan devices are used. New radiotracers will be needed in the evolution of PET to obtain information about more specific aspects of prostate carcinoma that will modify therapy and follow-up.
Keywords : PET; Prostate cancer; Follow-up.